Posted by Michael Wonder on 17 Sep 2017
Samsung Bioepis first to receive positive CHMP opinion on a trastuzumab biosimilar with Ontruzant
15 September 2017 - Ontruzant is the first biosimilar candidate referencing Herceptin (trastuzumab) to receive a positive opinion from the EMA’s CHMP.
Samsung Bioepis today announced that the EMA CHMP has adopted a positive opinion on Ontruzant, a biosimilar candidate referencing Herceptin (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.
